| Recruiting | A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2 NCT06240728 | NextPoint Therapeutics, Inc. | Phase 1 |
| Suspended | A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 NCT05958199 | NextPoint Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | Cryoablation for the Treatment of Metastatic Cancer NCT04150939 | M.D. Anderson Cancer Center | N/A |
| Recruiting | Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer NCT04068649 | Roswell Park Cancer Institute | Phase 2 |
| Active Not Recruiting | Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Ca NCT03743649 | M.D. Anderson Cancer Center | Phase 2 / Phase 3 |
| Active Not Recruiting | Financial Distress in Advanced Cancer Patients NCT04053517 | M.D. Anderson Cancer Center | — |
| Withdrawn | Ride to Care - Quality of Life With Transportation for RT NCT03849742 | University of California, San Francisco | N/A |
| Completed | Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and NCT03856060 | M.D. Anderson Cancer Center | N/A |
| Completed | Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings NCT04186884 | M.D. Anderson Cancer Center | — |
| Completed | 18F-FDG PET-MRI for Planning and Follow-Up of Patients With Spine Tumors Treated With Spine Stereotactic Radio NCT05174026 | M.D. Anderson Cancer Center | N/A |
| Terminated | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating P NCT03439085 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer NCT03671226 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy NCT03525873 | M.D. Anderson Cancer Center | Phase 3 |
| Active Not Recruiting | Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recu NCT03021486 | M.D. Anderson Cancer Center | Phase 2 / Phase 3 |
| Terminated | Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes NCT02774291 | Albert Einstein College of Medicine | EARLY_Phase 1 |
| Completed | Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors NCT03108131 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by S NCT02583269 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism NCT02585713 | Academic and Community Cancer Research United | Phase 3 |
| Completed | Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Rem NCT02540876 | University of Chicago | Phase 1 |
| Active Not Recruiting | Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer NCT02491632 | M.D. Anderson Cancer Center | Phase 2 / Phase 3 |
| Active Not Recruiting | Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations i NCT02286687 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II) NCT02152254 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melan NCT01592968 | M.D. Anderson Cancer Center | Phase 3 |
| Terminated | Gene Electrotransfer to Muscle With Plasmid AMEP in Patients With Disseminated Cancer NCT01664273 | Copenhagen University Hospital at Herlev | Phase 1 |
| Completed | Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers NCT01624766 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer NCT01582191 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With NCT01552434 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mu NCT01531361 | M.D. Anderson Cancer Center | Phase 1 |